The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Defibrillators


Psychiatry related information on Defibrillators


High impact information on Defibrillators

  • Clinical and genetic risk stratification may lead to prospective trials of primary implantation of cardioverter defibrillators in people with hereditary cardiomyopathy [7].
  • After February 1985, because the availability of the defibrillator was severely curtailed, patients who lost consciousness received treatment with amiodarone alone (group B) [8].
  • Among the 201 ICDs with integrated bipolar sensing, 80 were connected to a CPI device (60 Ventak 1600-Endotak 60 series and 20 PRx II 1715-Endotak 70 series) and 121 to the Ventritex defibrillator (91 Endotak 60 series, 14 TVL systems, and 16 Endotak 70 series) [9].
  • Nine patients are alive, 3 with implanted defibrillators and 6 treated with verapamil alone [10].
  • The hermetically sealed defibrillator is encased in titanium, weighs 250 g and has a volume of 145 ml [11].

Chemical compound and disease context of Defibrillators


Biological context of Defibrillators


Anatomical context of Defibrillators


Associations of Defibrillators with chemical compounds


Gene context of Defibrillators

  • Automated external defibrillators: an update of additions to the ACLS algorithms [29].
  • Fifteen patients undergoing defibrillator implantation were studied to compare the efficacy of the catheter with that of the superior vena cava spring (6.7 cm2, anode)-left ventricular patch (13.5 cm2, cathode) electrode system using truncated exponential waveforms with 60% tilt [30].
  • CONCLUSIONS: Beta-blocker use was independently associated with improved survival in patients with VF or symptomatic VT who were not treated with specific antiarrhythmic therapy, but a protective effect was not prominent in patients already receiving amiodarone or a defibrillator [31].
  • Release of neuron-specific enolase and s100 after implantation of cardioverters/defibrillators [32].
  • Both devices (the Philips FR2 or the HS1) are used in public access defibrillator settings [33].

Analytical, diagnostic and therapeutic context of Defibrillators


  1. Determination of ventricular vulnerable period and ventricular fibrillation threshold by use of T-wave shocks in patients undergoing implantation of cardioverter/defibrillators. Hou, C.J., Chang-Sing, P., Flynn, E., Martinez, L., Peterson, J., Ottoboni, L.K., Liem, L.B., Sung, R.J. Circulation (1995) [Pubmed]
  2. Predictors of arrhythmic death and cardiac arrest in the ESVEM trial. Electrophysiologic Study Versus Electromagnetic Monitoring. Caruso, A.C., Marcus, F.I., Hahn, E.A., Hartz, V.L., Mason, J.W. Circulation (1997) [Pubmed]
  3. Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator. Knight, B.P., Goyal, R., Pelosi, F., Flemming, M., Horwood, L., Morady, F., Strickberger, S.A. J. Am. Coll. Cardiol. (1999) [Pubmed]
  4. Optimising the use of beta-adrenoceptor antagonists in coronary artery disease. Ellison, K.E., Gandhi, G. Drugs (2005) [Pubmed]
  5. Molecular and phenotypic effects of heterozygous, homozygous, and compound heterozygote myosin heavy-chain mutations. Alpert, N.R., Mohiddin, S.A., Tripodi, D., Jacobson-Hatzell, J., Vaughn-Whitley, K., Brosseau, C., Warshaw, D.M., Fananapazir, L. Am. J. Physiol. Heart Circ. Physiol. (2005) [Pubmed]
  6. Bystander vs EMS first-responder CPR: initial rhythm and outcome in witnessed nonmonitored out-of-hospital cardiac arrest. Swor, R.A., Boji, B., Cynar, M., Sadler, E., Basse, E., Dalbec, D.L., Grubb, W., Jacobson, R., Jackson, R.E., Maher, A. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. (1995) [Pubmed]
  7. Cardiomyopathies: from genetics to the prospect of treatment. Franz, W.M., Müller, O.J., Katus, H.A. Lancet (2001) [Pubmed]
  8. The automatic implantable cardioverter-defibrillator in drug-refractory ventricular tachyarrhythmias. Fogoros, R.N., Fiedler, S.B., Elson, J.J. Ann. Intern. Med. (1987) [Pubmed]
  9. Undetected ventricular fibrillation in transvenous implantable cardioverter-defibrillators. Prospective comparison of different lead system-device combinations. Natale, A., Sra, J., Axtell, K., Akhtar, M., Newby, K., Kent, V., Geiger, M.J., Brandon, M.J., Kearney, M.M., Pacifico, A. Circulation (1996) [Pubmed]
  10. Short-coupled variant of torsade de pointes. A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias. Leenhardt, A., Glaser, E., Burguera, M., Nürnberg, M., Maison-Blanche, P., Coumel, P. Circulation (1994) [Pubmed]
  11. A chronically implanted system for automatic defibrillation in active conscious dogs. Experimental model for treatment of sudden death from ventricular fibrillation. Mirowski, M., Mower, M.M., Langer, A., Heilman, M.S., Schreibman, J. Circulation (1978) [Pubmed]
  12. Treatment of ventricular arrhythmias in patients with hypertrophic cardiomyopathy. Almendral, J.M., Ormaetxe, J., Martínez-Alday, J.D., Villacastin, J.P., Arenal, A., Pastor, A., Medina, O., Peinado, R., Delcan, J.L. Eur. Heart J. (1993) [Pubmed]
  13. Comparison of metoprolol and sotalol in preventing ventricular tachyarrhythmias after the implantation of a cardioverter/defibrillator. Seidl, K., Hauer, B., Schwick, N.G., Zahn, R., Senges, J. Am. J. Cardiol. (1998) [Pubmed]
  14. Effects of acute and prolonged administration of propafenone on internal defibrillation in the pig. Natale, A., Montenero, A.S., Bombardieri, G., Barilaro, C., Kim, Y.H., Klein, G.J., Jones, D.L. Am. Heart J. (1992) [Pubmed]
  15. Prognostic value of the QRS duration in patients with heart failure: a subgroup analysis from 24 centers of Val-HeFT. Hofmann, M., Bauer, R., Handrock, R., Weidinger, G., Goedel-Meinen, L. J. Card. Fail. (2005) [Pubmed]
  16. Effect of verapamil on prevention of atrial fibrillation in patients implanted with an implantable atrial defibrillator. Tse, H.F., Wang, Q., Yu, C.M., Ayers, G.M., Lau, C.P. Clinical cardiology. (2001) [Pubmed]
  17. I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. Arora, R., Ferrick, K.J., Nakata, T., Kaplan, R.C., Rozengarten, M., Latif, F., Ng, K., Marcano, V., Heller, S., Fisher, J.D., Travin, M.I. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. (2003) [Pubmed]
  18. Quality of BLS decreases with increasing resuscitation complexity. Rittenberger, J.C., Guimond, G., Platt, T.E., Hostler, D. Resuscitation. (2006) [Pubmed]
  19. Nonreversed saphenous vein grafts for coronary artery bypass grafting. Molina, J.E. Ann. Thorac. Surg. (1989) [Pubmed]
  20. Transesophageal echocardiographic evaluation of tricuspid valve regurgitation during pacemaker and implantable cardioverter defibrillator lead extraction. Roeffel, S., Bracke, F., Meijer, A., Van Gelder, B., Van Dantzig, J.M., Botman, C.J., Peels, K. Pacing and clinical electrophysiology : PACE. (2002) [Pubmed]
  21. Matching approved "nondedicated" hardware to obtain biventricular pacing and defibrillation: feasibility and troubleshooting. Kanagaratnam, L., Pavia, S., Schweikert, R., Marrouche, N., Lam, C., Abreu, M., Ching, E., Chung, M., Saliba, W., Niebauer, M., Wilkoff, B., Tchou, P., Natale, A. Pacing and clinical electrophysiology : PACE. (2002) [Pubmed]
  22. Accidental left ventricular placement of a defibrillator probe due to a patent foramen ovale in arrhythmogenic right ventricular dysplasia. Hagenah, G., Andreas, S., Konstantinides, S. Acta cardiologica. (2004) [Pubmed]
  23. Implantation of dual chamber pacemaker defibrillator and placement of endocardial leads via the axillary vein. Yang, J., Powell, A., Davis, M. Chin. Med. J. (2001) [Pubmed]
  24. A randomized trial comparing heparin initiation 6 h or 24 h after pacemaker or defibrillator implantation. Michaud, G.F., Pelosi, F., Noble, M.D., Knight, B.P., Morady, F., Strickberger, S.A. J. Am. Coll. Cardiol. (2000) [Pubmed]
  25. Acute effects of adrenergic agents on post-defibrillation arrest time in a cultured heart model. Krauthamer, V., Smith, T.C. Cell. Mol. Life Sci. (2004) [Pubmed]
  26. Effect of sotalol on ventricular fibrillation and defibrillation in humans. Dorian, P., Newman, D. Am. J. Cardiol. (1993) [Pubmed]
  27. Electrical proarrhythmia with procainamide: a new ICD-drug interaction. Fiksinski, E., Martin, D., Venditti, F. J. Cardiovasc. Electrophysiol. (1994) [Pubmed]
  28. Propofol reduces idiopathic prolonged QT interval and QT dispersion during implantation of cardioverter defibrillator. Michaloudis, D., Kanoupakis, E. Anesth. Analg. (2003) [Pubmed]
  29. Automated external defibrillators: an update of additions to the ACLS algorithms. Barbiere, C.C., Liberatore, K. Critical care nurse. (1992) [Pubmed]
  30. Comparison of defibrillation efficacy in humans using a new catheter and superior vena cava spring-left ventricular patch electrodes. Winkle, R.A., Bach, S.M., Mead, R.H., Gaudiani, V.A., Stinson, E.B., Fain, E.S., Schmidt, P. J. Am. Coll. Cardiol. (1988) [Pubmed]
  31. Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. Exner, D.V., Reiffel, J.A., Epstein, A.E., Ledingham, R., Reiter, M.J., Yao, Q., Duff, H.J., Follmann, D., Schron, E., Greene, H.L., Carlson, M.D., Brodsky, M.A., Akiyama, T., Baessler, C., Anderson, J.L. J. Am. Coll. Cardiol. (1999) [Pubmed]
  32. Release of neuron-specific enolase and s100 after implantation of cardioverters/defibrillators. Pelinka, L.E., Schmid-Hammer, R., Redl, H., Bahrami, S. Crit. Care Med. (2004) [Pubmed]
  33. Human factors impact successful lay person automated external defibrillator use during simulated cardiac arrest. Callejas, S., Barry, A., Demertsidis, E., Jorgenson, D., Becker, L.B. Crit. Care Med. (2004) [Pubmed]
  34. Halothane, isoflurane, and fentanyl increase the minimally effective defibrillation threshold of an implantable cardioverter defibrillator: first report in humans. Weinbroum, A.A., Glick, A., Copperman, Y., Yashar, T., Rudick, V., Flaishon, R. Anesth. Analg. (2002) [Pubmed]
  35. Nonpharmacological therapy of ventricular tachyarrhythmias: observations in 554 patients. Trappe, H.J., Pfitzner, P., Figuth, H.G., Wenzlaff, P., Kielblock, B., Klein, H. Pacing and clinical electrophysiology : PACE. (1994) [Pubmed]
  36. Is dual defibrillator better than conventional DDD pacing in brady-tachy syndrome? Results of the ICARUS Trial (Internal Cardioversion Antitachypacing and Prevention: Resource Utilization Study). Santini, M., Ricci, R., Pignalberi, C., Russo, M., Magris, B., Grovale, N., De Santo, T. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing. (2005) [Pubmed]
  37. Ventricular tachycardia associated with removal of a Swan-Ganz catheter. Shimm, D.S., Rigsby, L. Postgraduate medicine. (1980) [Pubmed]
  38. Basic life support and emergency cardiovascular care guidelines, Part 2: Defibrillators. Ryan, W.A. Dentistry today. (2001) [Pubmed]
WikiGenes - Universities